Clinical Trial Update: Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating renal effects of the DPP-4 inhibitor linagliptin in type 2 diabetes; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tradjenta (linagliptin) (linagliptin)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED